In ₹ Crore except Per Share Latest Annual | BALPHARMA FY26 | ALPA FY26 | KREBSBIO FY26 | NATCAPSUQ FY26 | Peer Median | |
|---|---|---|---|---|---|---|
| Valuation — at last close | ||||||
| P/E | 26.71× | ◆ 9.27× | — | — | 9.27× +188% | |
| P/B | 2.04× | ◆ 0.70× | — | — | 0.70× +191% | |
| EV/EBITDA | 10.13× | -0.70× | ◆ -65.36× | — | -33.03× +131% | |
| Market Cap | ₹168 Cr | ₹131 Cr | ₹132 Cr | — | ₹131 Cr +28% | |
| Growth | ||||||
| Revenue CAGR 3Y | 0.81% | ◆ 4.61% | -23.07% | — | -9.23% +109% | |
| Revenue CAGR 5Y | ◆ 4.46% | 1.64% | -15.07% | — | -6.71% +166% | |
| Net Income CAGR 3Y | ◆ 34.14% | 3.80% | — | — | 3.80% +798% | |
| Revenue YoY (latest Q) | ◆ 34.53% | 25.22% | 27.42% | 7.76% | 25.22% +37% | |
| Net Income YoY (latest Q) | ◆ 445.66% | -91.67% | 53.33% | -2.93% | -2.93% +15310% | |
| Profitability | ||||||
| EBITDA Margin | ◆ 10.24% | 3.11% | -22.97% | -0.83% | -0.83% +1334% | |
| Net Income Margin | 2.03% | ◆ 13.35% | -71.35% | -13.17% | -13.17% +115% | |
| Return on Common Equity | 7.64% | 7.58% | ◆ 10.40% | -7.27% | 7.58% +1% | |
| Return on Capital Employed | ◆ 16.49% | 0.63% | -23.66% | -6.42% | -6.42% +357% | |
| Return on Assets | 1.68% | ◆ 5.83% | -10.37% | -5.81% | -5.81% +129% | |
| Credit & Quality | ||||||
| Total Debt/Equity | 1.94× | 0.01× | ◆ -1.38× | 0.49× | 0.01× +19300% | |
| Interest Coverage | 1.24× | ◆ 4.65× | -1.68× | -1.71× | -1.68× +174% | |
| Scale — latest FY | ||||||
| Revenue / Total Income | ₹312 Cr | ₹106 Cr | ₹23.7 Cr | ₹187 Cr | ₹106 Cr +195% | |
| Net Income | ₹6.3 Cr | ₹14.1 Cr | −₹16.9 Cr | −₹24.7 Cr | −₹16.9 Cr +137% | |
| Total Assets | ₹376 Cr | ₹242 Cr | ₹163 Cr | ₹424 Cr | ₹242 Cr +55% | |
| EPS | ₹3.95 | ₹6.71 | ₹-7.85 | ₹-23.84 | ₹-7.85 +150% | |
| Book Value per Share | ₹51.66 | ₹88.53 | ₹-75.49 | ₹225.99 | ₹88.53 -42% | |